{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,14]],"date-time":"2023-06-14T14:28:45Z","timestamp":1686752925382},"reference-count":10,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2019,9,17]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Programmed cell death protein 1 (PD-1) and its ligand, PD-L1, have\nshown great promise in clinical practice and have been incorporated into standard management of\nNSCLC. Pneumonitis is a serious autoimmune toxicity associated with the use of anti-PD-1\/PD-L1\nantibodies, resulting in significant morbidity and mortality.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p> We described the case of a 73-year-old woman with no history of smoking developing\nexertional dyspnea four months after taking Pembrolizumab.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>High resolution contrast CT scan (HRCT) presented a unilateral \u201ccrazy paving\u201d pattern,\nand bronchoalveolar lavage (BAL) an important lymphocytosis (20% of total cell count). The patient\nreached clinical stability after the administration of systemic steroids (2mg\\Kg\\die) and was\ndischarged with long term oxygen therap<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Discussion:<\/jats:title>\n<jats:p>Pulmonary toxicity is frequent when using PD-1 inhibitors, resulting in significant\nmorbidity and mortality, often leading to the discontinuation of therapy. Clinical presentation is\nusually protean and HRCT pattern is nonspecific. This is the first case presenting a \u201ccrazy paving\u201d\npattern associated with BAL lymphocytosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Oncologists, pulmonologists, radiologists and general practitioners have to consider\nPD-1 and PD-L1 inhibitor pneumonitis as a potentially disabling and fatal event.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1574886314666190312115648","type":"journal-article","created":{"date-parts":[[2019,3,13]],"date-time":"2019-03-13T11:58:57Z","timestamp":1552478337000},"page":"242-245","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A \u201cCrazy Paving\u201d Pattern on CT Scan in a Patient Treated with Pembrolizumab"],"prefix":"10.2174","volume":"14","author":[{"given":"Maurizio","family":"Marvisi","sequence":"first","affiliation":[{"name":"Depertment of Internal Medicine, Istituto Figlie di San Camillo, Cremona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Ramponi","sequence":"additional","affiliation":[{"name":"Depertment of Internal Medicine, Istituto Figlie di San Camillo, Cremona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Balzarini","sequence":"additional","affiliation":[{"name":"Depertment of Internal Medicine, Istituto Figlie di San Camillo, Cremona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Mancini","sequence":"additional","affiliation":[{"name":"Depertment of Internal Medicine, Istituto Figlie di San Camillo, Cremona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.chest.2018.08.1048","volume":"154","author":"Suresh K.","year":"2018","unstructured":"Suresh K.; Naidoo J.; Ting Lin C.; Immune checkpoint immunotherapy for non-small cell lung cancer. Chest 2018,154,1416-1423","journal-title":"Chest"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-15-2998","volume":"22","author":"Morgensztern D.","year":"2016","unstructured":"Morgensztern D.; Herbst R.S.; Nivolumab and pembrolizumab for non-small cell lung cancer. Clin Cancer Res 2016,22,3713-3717","journal-title":"Clin Cancer Res"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"Pardoll D.M.","year":"2012","unstructured":"Pardoll D.M.; The blockade of immune check points in cancer immunotherapy. Nat Rev Cancer 2012,12,252-264","journal-title":"Nat Rev Cancer"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","volume":"2","author":"Nishino M.","year":"2016","unstructured":"Nishino M.; Giobbie-Hurder A.; Fatabu H.; Incidence of programmed cell death 1 inhibitor related pneumonitis in patents with advance cancer: A systematic review and meta-analysis. JAMA Oncol 2016,2,1607-1616","journal-title":"JAMA Oncol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.chest.2017.04.177","volume":"152","author":"Khunger M.","year":"2017","unstructured":"Khunger M.; Rakshit S.; Pasupuleti V.; Incidence of pneumonitis with use of PD-1 and PD-L1 inhibitors in non-small cell lung cancer: A systematic review and meta-analysis of clinical trials. Chest 2017,152,271-281","journal-title":"Chest"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"Naidoo J.","year":"2017","unstructured":"Naidoo J.; Page D.B.; Li B.T.; Pneumonitis in patients treated with PD-1 and PD-L1 therapy. J Clin Oncol 2017,35,709-717","journal-title":"J Clin Oncol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"Nishino M.","year":"2016","unstructured":"Nishino M.; Ramaya N.H.; Award M.M.; PD-1 inhibitor related pneumonitis in advance cancer patients: Radiographic pattern and clinical course. Clin Cancer Res 2016,22,6051-6060","journal-title":"Clin Cancer Res"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"00081","DOI":"10.1183\/23120541.00081-2016","volume":"3","author":"Leroy V.","year":"2017","unstructured":"Leroy V.; Templier C.; Faivre J-B.; Pembrolizumab-induced pneumonitis. ERJ Open Res 2017,3,00081-02016","journal-title":"ERJ Open Res"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1200\/JCO.2007.12.4784","volume":"25","author":"Trotti A Colevas A.D.","year":"2007","unstructured":"Trotti A Colevas A.D.; Setser A.; Patients reported outcomes and the evolution of adverse events report in oncology. J Clin Oncol 2007,25,5121-5127","journal-title":"J Clin Oncol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"Puzanov I.","year":"2017","unstructured":"Puzanov I.; Diab A.; Abdallah K.; Management toxicities associated with immune check point inhibitors consensus recommendations from the Society of Immunotherapy of cancer toxicity management working group. J Immunother Cancer 2017,5,95","journal-title":"J Immunother Cancer"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170646","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,18]],"date-time":"2019-10-18T16:12:19Z","timestamp":1571415139000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170646\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9,17]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886314666190312115648","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-09-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}